207 |
AKT SERINE/THREONINE KINASE 1 |
AKT1 |
AKT |
CWS6 |
PKB |
PKB-ALPHA |
PRKBA |
RAC |
RAC-ALPHA |
164730 |
391 |
ENSG00000142208 |
OTTHUMG00000170795 |
Proto-oncogene c-Akt |
PKB alpha |
RAC-PK-alpha |
Protein kinase B alpha |
Protein kinase B |
RAC-alpha serine/threonine-protein kinase |
2 |
P31749 |
AKT1_HUMAN |
PA24684 |
RAC-ALPHA SERINE/THREONINE-PROTEIN KINASE (EC 2.7.1.37) (RAC-PK-ALPHA) (PROTEIN KINASE B) (PKB) (C-AKT). [SOURCE:UNIPROT/SWISSPROT;ACC:P31749] |
T67619 |
Human Readable Name | DRUGGABLE GENOME |
CancerCommons Reported Gene Name | AKT |
Target Class | Enzymes |
Target Subclass | EC:2.7.11.1 |
Uniprot Status | Swiss-Prot |
Human Readable Name | KINASE |
Interpro Name | Serine/threonine- / dual-specificity protein kinase, catalytic domain |
Interpro Short Name | Ser/Thr_dual-sp_kinase_dom |
Interpro Type | Domain |
Uniprot Evidence | 1: Evidence at protein level |
Interpro Acc | IPR002290 |
Gene Biotype | PROTEIN_CODING |
TRANSPORTER |
KINASE |
SERINE THREONINE KINASE |
DRUG RESISTANCE |
DRUGGABLE GENOME |
CLINICALLY ACTIONABLE |
ENZYME |
TRANSCRIPTION FACTOR |
inhibitor (inhibitory) |
Approval Status | Phase II |
Response Type | predicted – sensitive |
Indication/Tumor Type | triple-receptor negative breast cancer |
inhibitor (inhibitory) |
Trial Name | perifosine, KRX-0401 |
Novel drug target | Novel Target |
Indication/Tumor Type | ovarian clear cell carcinoma |
inhibitor (inhibitory) |
Indication/Tumor Type | ovarian cancer |
Evidence Type | Actionable |
Approval Status | Phase I |
n/a |
Novel drug target | Novel Target |
Trial Name | RX-0201 ,Archexin |
combination therapy | Everolimus + RX-0201 |
n/a |
Evidence Type | Actionable |
Approval Status | Phase I |
Response Type | no benefit |
allosteric modulator |
inhibitory allosteric modulator (inhibitory) |
inhibitor (inhibitory) |
Notes | |
combination therapy | MK2206 + Vemurafenib |
Indication/Tumor Type | melanoma |
inhibitor (inhibitory) |
Mechanism of Interaction | Serine/threonine-protein kinase AKT inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | Serine/threonine-protein kinase AKT inhibitor |
inhibitor (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | Serine/threonine-protein kinase AKT inhibitor |
Novel drug target | Novel Target |
inhibitor (inhibitory) |
Mechanism of Interaction | Serine/threonine-protein kinase AKT inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | Serine/threonine-protein kinase AKT inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | Serine/threonine-protein kinase AKT inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | Serine/threonine-protein kinase AKT inhibitor |
allosteric modulator |
inhibitor (inhibitory) |
Mechanism of Interaction | Serine/threonine-protein kinase AKT inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | Serine/threonine-protein kinase AKT inhibitor |
inhibitor (inhibitory) |
Mechanism of Interaction | Serine/threonine-protein kinase AKT inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Notes |
inhibitor (inhibitory) |
Mechanism of Interaction | Serine/threonine-protein kinase AKT inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
inhibitor (inhibitory) |
Evidence Type | Actionable |
Approval Status | Phase Ib/II |
Response Type | sensitive |
n/a |
Indication/Tumor Type | endometrial cancer |
Response Type | sensitive |
Approval Status | Phase II |
inhibitor (inhibitory) |
Notes |
n/a |
combination therapy | Cisplatin + Gemcitabine + Sorafenib |
Indication/Tumor Type | invasive bladder transitional cell carcinoma |
Response Type | predicted – resistant |
n/a |
combination therapy | Cisplatin + Gemcitabine + Sorafenib |
Indication/Tumor Type | invasive bladder transitional cell carcinoma |
Response Type | predicted – resistant |
n/a |
combination therapy | Ipatasertib + Paclitaxel |
Indication/Tumor Type | triple-receptor negative breast cancer |
Response Type | predicted – sensitive |
AKT1 | Ensembl Gene Name |
Gene Biotype | PROTEIN_CODING |
AKT1 | Gene Symbol |
Target Class | Enzymes |
Target Subclass | EC:2.7.11.1 |
RAC-ALPHA SERINE/THREONINE-PROTEIN KINASE (EC 2.7.1.37) (RAC-PK-ALPHA) (PROTEIN KINASE B) (PKB) (C-AKT). [SOURCE:UNIPROT/SWISSPROT;ACC:P31749] | Description |
ENSG00000142208 | Ensembl Gene Id |
AKT1 | Display Id |
Human Readable Name | DRUGGABLE GENOME |
DRUGGABLE GENOME |
P31749 | Uniprot Accession |
RAC-ALPHA SERINE/THREONINE-PROTEIN KINASE | Uniprot Protein Name |
207 | Entrez Gene Id |
Uniprot Status | Swiss-Prot |
Human Readable Name | KINASE |
Interpro Name | Serine/threonine- / dual-specificity protein kinase, catalytic domain |
KINASE, DRUGGABLE GENOME |
207 | Entrez Gene ID |
CancerCommons Reported Gene Name | AKT |
207 | CKB Entrez Id |
AKT1 | CKB Gene Synonym |
AKT | CKB Gene Synonym |
PA24684 | PharmGKB ID |
207 | Entrez Gene ID |
2 | CIViC Gene ID |
DRUG RESISTANCE |
ENSG00000142208 | Gene Symbol |
AKT1 | Ensembl Id |
DRUGGABLE GENOME |
207 | Entrez Gene Id |
AKT1 | MyCancerGenome Gene Symbol |
AKT | MyCancerGenome Reported Gene Name |
AKT | Gene Symbol |
RAC | GENE_SYMBOL |
AKT1 | GENE_SYMBOL |
RAC-alpha serine/threonine-protein kinase | UNIPROT |
207 | OncoKB Entrez Id |
PRKBA | OncoKB Gene Synonym |
RAC | OncoKB Gene Synonym |
ENSG00000142208 | Ensembl Gene ID |
AKT | Human Protein Atlas Gene Synonym |
PKB | Human Protein Atlas Gene Synonym |
ENZYME |
PKB | GO Gene Synonym |
RAC | GO Gene Synonym |
KINASE, SERINE THREONINE KINASE |
AKT1 | Gene Symbol |
CLINICALLY ACTIONABLE |
207 | Gene ID |
AKT | dGene Synonym |
PKB | dGene Synonym |
KINASE, SERINE THREONINE KINASE |
AKT1 | TTD Gene Abbreviation |
T67619 | TTD Target ID |
RAC-alpha serine/threonine-protein kinase | Gene Name |
P31749 | UniProt ID |
TRANSPORTER, KINASE, TRANSCRIPTION FACTOR |
CLINICALLY ACTIONABLE |
CLINICALLY ACTIONABLE |
CLINICALLY ACTIONABLE |
CLINICALLY ACTIONABLE |